FATE Latest Press Releases

-- October 26, 2026 --

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026 Globe Newswire 7:00 AM

-- October 12, 2026 --

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies Globe Newswire 7:00 AM

-- October 6, 2026 --

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise Globe Newswire 8:00 AM

-- October 2, 2026 --

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- October 1, 2026 --

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences Globe Newswire 7:00 AM

-- September 25, 2026 --

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN Globe Newswire 7:00 AM

-- September 16, 2026 --

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 Globe Newswire 7:00 AM

-- September 9, 2026 --

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting Globe Newswire 7:00 AM

-- September 3, 2026 --

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference Globe Newswire 7:00 AM

-- August 14, 2026 --

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis Globe Newswire 7:00 AM

-- August 13, 2026 --

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates Globe Newswire 8:30 AM

-- August 3, 2026 --

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 9, 2026 --

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate Globe Newswire 8:30 AM

-- July 6, 2026 --

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting Globe Newswire 8:30 AM

-- July 1, 2026 --

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences Globe Newswire 4:05 PM

-- June 30, 2026 --

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PRNewswire 9:00 AM

-- June 15, 2026 --

Fate Therapeutics Appoints Laura Hamill to Board of Directors Globe Newswire 8:30 AM

-- June 12, 2026 --

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell Globe Newswire 8:10 AM

-- June 8, 2026 --

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet Globe Newswire 9:01 AM

-- June 4, 2026 --

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting Globe Newswire 8:30 AM

-- June 2, 2026 --

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 1, 2026 --

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting Globe Newswire 8:30 AM

Market Data Delayed 15 Minutes